GHDx
Published on GHDx (https://ghdx.healthdata.org)


The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study

General Info

Geography 
Fiji (FJI)
Haiti (HTI)
India (IND)
Indonesia (IDN)
Papua New Guinea (PNG)
Time period covered 
January, 2016 - December, 2017
Data type
Scientific literature
Keywords 
Lymphatic filariasis

Citation

Authors 
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS, Krishnamoorthy K, Laman M, Lemoine JF, O'Brian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, DOLF IDA Safety Study Group
Journal 
PLoS Med
Pages 
e1002839
Publication year 
2019
Suggested citation 
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS, Krishnamoorthy K, Laman M, Lemoine JF, O'Brian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, DOLF IDA Safety Study Group. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med. 2019; 16(6): e1002839.

Source URL:https://ghdx.healthdata.org/record/safety-double-and-triple-drug-community-mass-drug-administration-lymphatic-filariasis